March 20 (Reuters) - Eli Lilly LLY.N has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
(Reporting by Rishika Sadam and Manvi Pant; Editing by Janane Venkatraman)
((Manvi.Pant@thomsonreuters.com; +918447554364;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.